Diminished Ovarian Reserve — Diagnosis & Treatment Options

Receiving a diagnosis of diminished ovarian reserve (DOR) can feel like a door closing. The reality is more nuanced. DOR describes the quantity of eggs remaining in the ovaries — not their quality, and not an absolute verdict on your ability to conceive. With the right protocol and realistic expectations, many women with DOR achieve pregnancy, sometimes with their own eggs and sometimes with donor eggs.

This guide explains what DOR means, how it is measured, and what the full range of treatment options looks like based on current evidence.

What Is Diminished Ovarian Reserve?

For treatment pathways and what to expect at a fertility clinic, see our diminished ovarian reserve guide.

Every woman is born with a finite number of primordial follicles — the precursors to eggs. This pool peaks before birth and declines continuously throughout life, with no new follicles ever formed. Ovarian reserve refers to the size of this remaining pool.

Diminished ovarian reserve (DOR) means the pool is smaller than expected for a woman's age. It is not the same as:

• Poor egg quality — reserve and quality are related but not identical. A 28-year-old with DOR may still have high-quality eggs, while a 42-year-old with normal reserve for her age may have more chromosomally abnormal eggs.
• Premature ovarian insufficiency (POI) — POI is a more severe condition defined by menstrual irregularity, elevated FSH, and estrogen deficiency before age 40. DOR describes reduced reserve without necessarily meeting POI criteria.
• Infertility — DOR reduces the probability of conceiving in a given cycle and lowers the response to fertility medications, but it does not categorically prevent pregnancy.

How DOR Is Diagnosed: Key Markers and Thresholds

Three tests are used in combination to assess ovarian reserve. No single test is definitive; the picture is most accurate when all three are interpreted together.

Anti-Müllerian Hormone (AMH)

AMH is secreted by small antral follicles and reflects the size of the remaining follicle pool. It is the most stable marker — it can be measured on any day of the menstrual cycle and varies little cycle to cycle.

These thresholds vary slightly by lab assay. The ASRM AMH committee guidance notes that low AMH predicts poor response to ovarian stimulation but is a weaker predictor of live birth rate per transfer once embryos are obtained.

Antral Follicle Count (AFC)

AFC is measured by transvaginal ultrasound on day 2–4 of the menstrual cycle. It counts visible antral follicles (2–10 mm) in both ovaries and directly reflects the cohort of follicles available for stimulation.

Day-3 FSH

Follicle-stimulating hormone (FSH) is measured on day 2–4 of the menstrual cycle. As the ovarian pool diminishes, the pituitary secretes more FSH in an attempt to drive follicle development.

FSH is more variable cycle to cycle than AMH. A single normal FSH does not rule out DOR if AMH or AFC is low. Elevated FSH in the context of irregular periods and estrogen deficiency raises concern for premature ovarian insufficiency.

Bologna Criteria: Defining the Poor Responder

The ESHRE Bologna criteria (2011) are the most widely used standardized definition of a poor ovarian responder (POR) in the context of IVF stimulation. A patient meets criteria if she has at least two of the following three features:

1. Advanced maternal age (>40 years) or another risk factor for poor response
2. A previous poor ovarian response (fewer than 3 oocytes retrieved with a conventional stimulation protocol)
3. An abnormal ovarian reserve test (AFC <5–7 or AMH <0.5–1.1 ng/mL)

If a patient has had two prior poor responses with a conventional protocol, she meets Bologna criteria regardless of age or reserve testing.

The POSEIDON classification (2016) expanded on Bologna to create four patient groups that guide personalized stimulation strategy — it distinguishes between unexpected poor responders (normal reserve but unexpectedly poor response) and expected poor responders (abnormal reserve), and further divides by age (below or above 35).

Treatment Options for Diminished Ovarian Reserve

1. Aggressive Stimulation (High-Dose Gonadotropins)

The first instinct when reserve is low is to use more FSH. Maximal stimulation protocols use doses of 450–600 IU/day of recombinant FSH, sometimes combined with LH. The rationale is to rescue follicles that would otherwise be lost.

The evidence on aggressive stimulation is mixed. A Cochrane review found no significant difference in live birth rates between higher and lower stimulation doses in poor responders. Very high doses may actually suppress response in some patients, and the incremental yield of eggs beyond a certain dose is limited. Many clinics have moved away from reflexively maximizing doses and toward protocol diversification.

2. Minimal Stimulation IVF (Mini-IVF)

Mini-IVF uses lower doses of gonadotropins (or oral agents like clomiphene or letrozole) to recruit a small number of eggs — typically 1–5. The logic: if only 1–3 eggs are expected anyway with maximum stimulation, a lower-dose approach costs less, is gentler on the body, and may improve oocyte quality by reducing FSH-induced stress on the follicle microenvironment.

Some studies suggest that mini-IVF embryos may have comparable or even better euploidy rates per embryo compared to conventional high-dose cycles in poor responders — though live birth data per cycle are necessarily lower because fewer embryos are generated.

3. Natural Cycle IVF

Natural cycle IVF involves retrieving the single dominant follicle that develops without stimulation. It avoids gonadotropins entirely, costs less per cycle, and may be appropriate for women with extremely low reserve who produce only one follicle anyway. The trade-off: cycle cancellation rates are high (the dominant follicle may ovulate before retrieval), and a single egg per cycle means many cycles are needed to build a cohort.

4. Egg Banking (Cumulative Retrieval)

For women who produce 1–3 eggs per cycle, multiple back-to-back retrieval cycles can accumulate a bank of frozen eggs or embryos before attempting transfer. This strategy converts a poor-prognosis situation into a numbers game — the aim is to generate enough embryos to have at least one euploid embryo to transfer.

Our egg freezing and vitrification guide covers the technical aspects of egg banking in detail.

5. Donor Eggs

Donor egg IVF remains the most effective option for women with severely diminished ovarian reserve, offering live birth rates of 40–55% per transfer that are largely independent of the recipient's age — because the eggs reflect the donor's age (typically under 32). Most clinics report that donor egg cycles with young, healthy donors achieve clinical pregnancy rates exceeding those of conventional IVF at any age.

The decision to use donor eggs is deeply personal and often emotionally complex. Many patients benefit from counseling before committing to this path. Working with an experienced reproductive endocrinologist to set realistic expectations for own-egg cycles is important before moving to donor eggs — but delaying the discussion indefinitely when reserve is very low also carries the real cost of time.

Exploring Conception Options?

For women with diminished ovarian reserve exploring lower-intervention options alongside their clinical treatment, understanding all available paths matters.

MakeAMom makes reusable at-home insemination kits for couples and individuals trying to conceive at home: the CryoBaby for frozen or low-volume sperm, the Impregnator for low-motility sperm, and the BabyMaker for those with sensitivities. Kits ship discreetly and are designed for use without a clinic visit.

Explore home insemination kits at MakeAMom →

DHEA Supplementation: Does the Evidence Support It?

Dehydroepiandrosterone (DHEA) is an androgen precursor that has attracted significant attention as a potential adjunct for poor ovarian responders. The hypothesis is that intraovarian androgens support early follicle development, and that supplementing with DHEA (typically 75 mg/day for 6–16 weeks before IVF) may improve the number and quality of eggs retrieved.

The Cakmak and Rosen review (2015) summarized available evidence and found modest but consistent signals that DHEA pretreatment improves the number of oocytes retrieved and reduces cycle cancellation rates. Several randomized controlled trials have been conducted, with mixed results.

The ASRM DOR committee opinion acknowledges DHEA as a frequently used adjunct while noting that evidence from large, well-powered RCTs remains limited. Side effects include acne, oily skin, hair growth, and mood changes. DHEA should be used under medical supervision and ideally started at least 12 weeks before anticipated retrieval.

CoQ10 is another frequently discussed supplement. Mitochondrial function declines with age, and CoQ10 is theorized to support oocyte energy metabolism. Evidence is largely from animal models and small human studies; it is considered safe and reasonably supported for use in DOR patients, though not definitively proven to improve live birth rates.

Success Rate Estimates by Protocol

The following estimates are approximate and reflect aggregate data for women with DOR (<35 years old unless noted). Individual outcomes depend heavily on remaining egg quality, partner fertility, and clinic-specific protocols.

For women with AMH <0.5 ng/mL, cycle cancellation rates before retrieval can reach 30–40% in conventional stimulation cycles.

Prognosis and Counseling

One of the most important aspects of DOR management is honest, data-driven counseling. Studies consistently show that patients with DOR can and do conceive — both naturally and through IVF — but the probability per attempt is lower, and the number of cycles required to achieve a live birth is higher than for women with normal reserve.

Key prognostic factors:

• Age is the dominant variable. A 30-year-old with DOR has better egg quality than a 40-year-old with normal reserve.
• AMH <0.1 ng/mL is associated with very low cumulative live birth rates with own eggs, and donor egg counseling is appropriate early.
• Prior pregnancy with a partner is a favorable prognostic sign.
• Cause of DOR matters — women whose DOR was caused by prior ovarian surgery or endometrioma may have a different prognosis than those with idiopathic or genetic causes.

Key Takeaways

• DOR means reduced quantity of eggs, not necessarily reduced quality — age is the strongest quality determinant.
• Diagnosis requires at least two of the three markers (AMH, AFC, FSH) to be interpreted together.
• Bologna criteria formally define the poor ovarian responder in the IVF context.
• No stimulation protocol has proven definitively superior to others in terms of live birth per transfer; protocol choice should be individualized.
• DHEA supplementation has modest supportive evidence and is reasonable under medical supervision.
• Donor egg IVF is the most reliable option when own-egg cycles are repeatedly unsuccessful.

Frequently Asked Questions

Q: What is the difference between diminished ovarian reserve and premature ovarian insufficiency? A: Diminished ovarian reserve (DOR) describes a smaller-than-expected follicle pool for a woman's age, without necessarily meeting the criteria for a more severe diagnosis. Premature ovarian insufficiency (POI) is a more severe condition defined by menstrual irregularity, elevated FSH (typically above 25 IU/L), and estrogen deficiency before age 40. DOR can exist without POI, and women with DOR may still have regular cycles.

Q: Does low AMH mean my eggs are poor quality? A: No. AMH reflects the quantity of eggs remaining, not their quality. Egg quality is primarily determined by age. A 28-year-old with DOR may still produce high-quality eggs, while a 42-year-old with normal reserve for her age may have a higher proportion of chromosomally abnormal eggs. The ASRM AMH committee guidance emphasizes that low AMH predicts poor IVF response (fewer eggs retrieved) but is a weaker predictor of live birth rate per embryo transferred.

Q: What are the Bologna criteria for poor ovarian response? A: The ESHRE Bologna criteria (2011) define a poor ovarian responder as a patient with at least two of three features: advanced maternal age (over 40) or another risk factor for poor response; a previous poor response of fewer than 3 oocytes with a conventional stimulation protocol; or an abnormal ovarian reserve test (AFC less than 5–7 or AMH less than 0.5–1.1 ng/mL).

Q: Does DHEA supplementation help women with diminished ovarian reserve? A: Evidence is mixed but shows modest signals of benefit. The Cakmak and Rosen review (2015) found consistent signals that DHEA pretreatment (typically 75 mg/day for 6–16 weeks before IVF) improves the number of oocytes retrieved and reduces cycle cancellation rates. The ASRM acknowledges DHEA as a frequently used adjunct while noting that evidence from large, well-powered RCTs remains limited. It should be used under medical supervision.

Q: What are realistic success rates for women with DOR attempting IVF with their own eggs? A: Success rates vary significantly by age and AMH level. For women with DOR under 35, conventional high-dose IVF produces clinical pregnancy rates of approximately 15–25% per cycle started, with median egg retrievals of 2–4. Mini-IVF produces 10–18% per cycle. Women with AMH below 0.1 ng/mL face cycle cancellation rates of 30–40% before retrieval and very low cumulative live birth rates with own eggs. Donor egg IVF offers 40–55% per transfer regardless of recipient age.

References

1. American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2015;103(3):e9–e17.
2. Ferraretti AP, et al. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26(7):1616–1624.
3. Cakmak H, Rosen MP. Systemic DHEA supplementation improves the response to ovulation induction. Curr Opin Obstet Gynecol. 2015;27(3):188–194.
4. Broer SL, et al. The role of antimüllerian hormone in prediction of outcome after IVF. Hum Reprod Update. 2009;15(3):255–266.
5. Oudendijk JF, et al. The poor responder in IVF. Hum Reprod Update. 2012;18(1):1–11.